Looking to expand your partner network with leading companies like Genkyotex? Consider joining Inpart's global network for free.
News and Trends 2 May 2019
Drug for Autoimmune Liver Disease Yields Mixed Results in Hard-to-Treat Patients
Developed by the French biotech Genkyotex, a first-in-class treatment for the liver disease primary biliary cholangitis failed to reduce a key disease biomarker in a phase II trial, but showed potential for reducing liver scarring. Primary biliary cholangitis is an autoimmune disease that damages the liver and can lead to liver scarring (fibrosis) or the […]
